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Introduction: Although there is an increase in clinical trials assessing the efficacy of cell therapy in structural and
functional regeneration after stroke, there are not enough data in the literature describing the best cell type to be
used, the best route, and also the best nanoparticle to analyze these stem cells in vivo. This review analyzed
published data on superparamagnetic iron oxide nanoparticle (SPION)-labeled stem cells used for ischemic stroke
therapy.
Method: We performed a systematic review and meta-analysis of data from experiments testing the efficacy of
cellular treatment with SPION versus no treatment to improve behavioral or modified neural scale outcomes in
animal models of stroke by the Cochrane Collaboration and indexed in EMBASE, PubMed, and Web of Science
since 2000. To test the impact of study quality and design characteristics, we used random-effects meta-regression.
In addition, trim and fill were used to assess publication bias.
Results: The search retrieved 258 articles. After application of the inclusion criteria, 24 reports published between
January 2000 and October 2014 were selected. These 24 articles were analyzed for nanoparticle characteristics, stem
cell types, and efficacy in animal models.
Conclusion: This study highlights the therapeutic role of stem cells in stroke and emphasizes nanotechnology as
an important tool for monitoring stem cell migration to the affected neurological locus.Introduction
Stroke has ranked recently as the second most common
cause of death in the Global Burden of Diseases, Injuries,
and Risk Factors Study (2010) [1] and as the third most
common cause of disability-adjusted life-years (DALYs)
worldwide (2010) [2]. Despite the heterogeneity of global
epidemiological data and the measurement bias in places
without trained professionals, evidence from developed
countries suggests that one out of 20 adults (more than* Correspondence: lgamarra@einstein.br
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unless otherwise stated.14 years old) is affected by stroke, and this exceeds the
current incidence of acute coronary heart disease. There-
fore, stroke constitutes the leading cause of mortality
among adults [3].
Conventional clinical management includes percutan-
eous intravascular interventions and thrombolytic ther-
apy or other medications such as aspirin and behavioral
rehabilitation strategies. The wide use of thrombolytic
therapy is limited by the narrow time window (within 3
to 4.5 hours after the onset of acute stroke) and serious
hemorrhagic complication [4]. Thrombolytic therapy
(recombinant tissue plasminogen activator, or rt-PA) is
still the most efficient procedure used to restrict neuro-
logical damage, although its effectiveness is dependent
on and limited to a narrow time window (3 to 4.5 hourshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hemorrhagic complication. Neuroprotective therapies or
other procedures, such as erythropoietin (EPO), N-methyl
d-aspartate (NMDA) antagonists, and gamma-aminobutyric
acid (GABA), have shown positive results in preclinical
stroke trials but no evidence of clinical efficacy [5,6].
Given this therapeutic setting, the use of stem cells or
stem cell therapy is emerging as a viable option for neu-
rorestorative stroke, especially in cases where the start
time of rt-PA exceeded the ideal. The stem cell therapy
promotes neuroprotection and neurorepair because of
their ability to produce and secrete neurotrophic factors,
and it stimulates the replacement of damaged neurons,
enabling a favorable neuroimmunomodulation environ-
ment for repair [6,7].
The route of administration is crucial for the success
of stem cell transplantation because tracking and moni-
toring of grafted cells are necessary, given the minimum
concentration of cells required for the surgery as de-
scribed earlier. Several techniques using nanoparticles—
quantum dots, pebbles, and superparamagnetic iron
oxide nanoparticles (SPIONs) [8]—have been described
to screen cells in vivo. The iron oxide and magnetic res-
onance imaging (MRI) can be used not only to evaluate
whether the cells have been successfully engrafted but
also to monitor the time course of cell migration in the
targeted tissue (Figure 1) [9].
This study evaluated functional outcome in publications
of the past decade about stem cells labeled with iron oxide
nanoparticles in a preclinical ischemic model. Considering
reports included in this review, we sought to provide a
comprehensive synopsis of preclinical evidence using vari-
ous donor cell types, their restorative mechanisms, deliveryFigure 1 Mesenchymal stem cell therapy after focal ischemia. Rat brai
labeled with superparamagnetic iron oxide nanoparticles after focal ischem
chloride after occlusion of the middle cerebral artery. (B-C) Umbilical cord
nanoparticles, with Prussian blue and rhodamine in fluorescence microscop
mesenchymal stem cell interactions with nanoparticles.methods, future prospects, and challenges for translating
cell therapies as a functional therapy for stroke in clinical
settings.Methods
Search strategy
We included reports between January 2000 and October
2014 that were found in the following databases:
Cochrane Library, EMBASE, PubMed, and Web of Sci-
ence. A Boolean strategy was applied. The following se-
quence of keywords and Boolean operators (DecS/
MeSH) were used: EMBASE: ‘stem cell’/exp OR ‘stem
cell’AND (‘iron oxide’/exp OR ‘iron oxide’ OR nanopar-
ticle) AND (‘stroke’/exp OR stroke OR ‘cerebral ische-
mia’); PubMed: (((stem cell [MeSH terms]) AND (iron
oxide OR SPIO OR nanoparticle)) AND ‘cerebral ische-
mia’) OR (((stem cell [MeSH terms]) AND (iron oxide
OR SPIO OR nanoparticle)) AND stroke); Web of Sci-
ence: TS = (stem cell) AND TS = (nanoparticle) AND
TS = (cerebral ischemia) OR TS = (stem cell) AND TS =
(nanoparticle) AND TS = (stroke) OR TS = (stem cell)
AND TS = (iron oxide) AND TS = (cerebral ischemia)
OR TS = (stem cell) AND TS = (iron oxide) AND TS =
(stroke); Cochrane Library: ‘stem cell’, ‘iron oxide’ OR
‘nanoparticle’AND ‘stroke’ .Data extraction
Two reviewing authors independently extracted data,
screened all references to verify eligibility, and assessed
the quality of the trial. Discrepancies in selection of
studies and data extraction that appeared between the
two reviewers were discussed with a third reviewer andn schematic figure of grafting process of the mesenchymal stem cells
ia. (A) Coronary rat brain slice staining with 2,3,5-triphenyltetrazolium
of mesenchymal stem cells labeled with superparamagnetic iron oxide
y, respectively; * focal ischemia. (D) Schematic representation of
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by using fixed-effect meta-analyses.
Study selection
Studies included were original reports written in English
that used stem cells labeled with paramagnetic iron oxide
nanoparticles (SC/SPIONs) in stroke preclinical models
published between January 2000 and October 2014. We
excluded from this review duplicate reports indexed in
more than one database, incomplete articles, studies in
conferences, congress or symposium format, book chap-
ters, and publications not in English or those not related
to nanoparticles of iron oxide or stem cells (Figure 2).
Statistical analysis
Data were analyzed by applying a meta-analysis approach
[10]. Heterogeneity was evaluated by using the I2 statistic;
a considerable heterogeneity (I2 > 50%) was explored by
using a fixed-effects model by the free software R version
3.1.0 (Free Software Foundation, Boston, MA, USA).
Results
In total, 268 articles were identified by the Cochrane Col-
laboration and indexed in PubMed, Web of Science, and
EMBASE. After inclusion criteria were applied, 24 studies
were selected (Figure 2). Of these, 20 (83%) were published
within the past 5 years (2008 to 2013). Most (52%) of the
studies were conducted in Asia, followed by the United
States and European countries.
The main characteristics of selected studies are pre-
sented in Table 1. In regard to the experimental model
adopted, one study [11] used dogs, two studies [12,13]
used New Zealand rabbits, three studies [14-16] used
mice, and other studies (77%) used rats (200 to 310 g). Ex-
perimental methods used were the lacunar method in one
study [17] and the photothrombosis method in four stud-
ies [18-21] conducted in Belgium. These studies used rose
Bengal (10 or 20 mg/kg) for 20 minutes and focused a
light beam of 540 nm. In addition, 18 of 19 other studies
[11-16,22-33] used the temporary occlusion method of a
cerebral vascular bed. Permanent occlusion was reported
only in studies by Reddy et al. [12], Gutiérrez-Fernández
et al. [34], Wang et al. [35], and Tarulli et al. [32]. The
remaining studies performed temporary occlusion, which
ranged from 5 minutes [13,16,31] to 120 minutes
[24,25,28]. The most common vascular beds used were
the middle cerebral artery as well as the internal carotid
artery of rabbits (New Zealand) [12,34] and the common
carotid artery of rats [13].
The labeling cells with SPIONs in most studies
[13,14,18,20,24-27,34] were Feridex (or Endorem), four
studies [13,19-21] used Resovist, two studies [20,22]
used Sinerem, and one study [13] used FluidMag-D,
FluidMag-lipid, DEAE-FluidMag, FluidMag-P, andFluidMag-Q. One study [29] used fluorescent iron
nanoparticles (excitation 480 nm and emission 250 nm).
In addition to the 13 studies that evaluated commercial
nanoparticles, four studies [12,15,19,30] evaluated
nanoparticles synthesized in the lab: (i) Lee et al. [19]
used nanoparticles synthesized from co-precipitation
and polymerization processes; however, these processes
were changed to obtain nanoparticles of different diam-
eters, such as 100 to 750 nm; (ii) Reddy et al. [12] used
magnetic nanoparticles synthesized by the sonochemical
method followed by coating with the Chitosana process;
(iii) in the study by Wang et al. [15], synthesis occurred
in two stages: the first stage generated synthesis of mag-
netite nanocluster polystyrene (PMNC), and the second
promoted a PMNC coat with silica and rhodamine
layer.
For cell process 1, the study [21] used adult progenitor
cells, two studies [26,27] used neural lineages, and 13
studies used mesenchymal stem cells (MSCs). Of these
13 trials, four did not specify the cell tissue origin
[13,18,20,24], four extracted mesenchymal cells from
bone marrow [12,25,29,30], one used fetal MSCs [19],
and two used stem cells extracted from tibia and femur
[15,34].
The majority of cells were from rats [7,18,21,25,30-34];
however, seven studies used human cells [12,19,24,26-29],
five studies used mice cells [14-16,20,23], one study used
dog cells [11], and one study used rabbit cells [13]. Only
one study did not specify cell type [22]. In relation to cell
concentration used for labeling with SPION, only four
studies reported this information [13,19,25,27]. The study
by Walczak et al. [25], among the identified studies, used
the highest cell concentration (1 × 106), two studies [19,27]
used the same cell concentration (5 × 105), and the study by
Riegler et al. [13] used only 104 cells. These cells were
grown mainly in Dulbecco’s modified Eagle’s medium
(DMEM) culture [2,14,18,19,22,26,27,34]. Of these seven
articles, one [26] used DMEM with F12, another [25] used
alpha-minimum essential medium (α-MEM) with F12, and
Detante et al. [29] used only α-MEM without F12. Only
one study [13] used a specific culture for MSCs, and the
other four studies [15,20,21,24] did not specify the culture
medium used. Of selected studies, only five [13,26,27,29,34]
reported behavior score; therefore, three [13,29,34] used
MSCs, and two used neural [27] or embryology [26] stem
cells (Figure 3).
When it comes to the analysis of the process of cell
labeling with nanoparticles or SPIONs, most studies
[12,14,20-22,24-26] used transfection agents. Of these
studies, six [12,14,20,21,25,26] used poly(l-lysine) (PLL), one
[22] used Fugene, one [24] used protamine sulfate as trans-
fector agent, and one [13] used serum deprivation as a
process of internalization. The most common SPION con-
centration in this process was approximately 374 μg/mL,
Figure 2 Flowchart of the article screening process for inclusion in this review. SPION, superparamagnetic iron oxide nanoparticle.
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Table 1 Motor performance after therapy with stem cells labeled by iron oxide nanoparticles in experimental designs of stroke
Reference Experimental model SPION Stem cell Behavioral score
Animal Type Type Type [Fe] μg/mL Source Type Concentration Route Time Sham Lesion
Wen et al. [33] (2014) Rat
(Sprague-Dawley)
MCDA T (N/A) In lab 26 Rat NSC 5 × 105 Str 2 d N/A N/A
Shichinohe et al.
[17] (2013)
Rat (Wistar) Lacunar T (N/A) Resovist 1 Rat BMSC 5 × 105 Str 7 d N/A N/A
Tarulli et al. [32]
(2013)
Rat (Long Evans) MCDA P MOC07F, Bang Lab. 18,8 Rat
(femur and tibia)
BMSC 3 × 106 V 3 d N/A N/A
Zhang et al. [16]
(2013)
Mice (CD-1) MCDA T (5 mi) In lab 5-33 Mice NSC 5 × 105 IC; V 1 d N/A N/A
Liu et al. [31] (2013) Rat
(Sprague-Dawley)
MCDA T (5 mi) In lab N/A Rat NSC 3 × 104 Str 2 d N/A N/A
Lu et al. [11] (2013) Dog (Beagle) MCDA T (2 h) In lab N/A Dog
(bone marrow)
MSC 3 × 106 IC 2 h N/A N/A
Kamiya et al. [30]
(2013)
Rat
(Sprague-Dawley)
MCDA T (90 mi) In lab N/A Rat
(femur and tibia)
MSC 107 (1 mL) IC 90
mi
N/A N/A
Riegler et al. [13]
(2012)
Rabbit
(New Zealand)
OAF T (5 mi) FluidMag-D, FluidMag-lipid,
FluidMag-DEAE, FluidMag,
Endorem, Resovist
16-56.0 Rabbit MSC 105 (300 μL) V 5 mi 2.9 ± 0.93 1.6 ± 0.38
Detante et al. [29]
(2012)
Rat
(Sprague-Dawley)
MCDA T (90 mi) In lab 10.0 Human
(bone marrow)
MSC 105 (5 μL) Str IC 7 d 3.3 ± 1.5 1.4 ± 0.8
Yang et al. [28]
(2011)
Rat
(Sprague-Dawley)
MCDA T (2 h) In lab 25 Human
(bone marrow)
MSC 6 × 105 IC 14 d N/A N/A
Wang et al. [15]
(2011)
Mice (CD-1) MCDA P; T (30 mi) In lab N/A Mice
(femur and tibia)
MSC 5 × 105 (1 μL) Str 0 d N/A N/A
Gutiérrez-Fernández
et al. [34] (2011)
Rat
(Sprague-Dawley)
MCDA P Endorem 11.2 Rat
(femur and tibia)
MSC 2 × 106 (650 μL) IC V 0 d 3.4 ± 0.89 1.7 ± 0.53
Vandeputte et al.
[21] (2011)
Rat (Fisher 344) FOT1 N/A Resovist 27.9 Rat rMAPC 106 (1 μL) Str 1 d N/A N/A
Reddy et al. [12]
(2010)
Rabbit
(New Zealand)
ICAO P Resovist 11.2 Human
(bone marrow)
MSC 106 (1 μL) IC 4 d N/A N/A
PPA
Crabbe et al. [20]
(2010)
Mice FOT1 N/A Resovist;
Endorem;
Sinerem
11.2-27.9 Mice MSC 104-5 × 106 Str 2 d N/A N/A
Rat (Fisher 344)
Song et al. [27]
(2009)
Rat
(Sprague-Dawley)
MCDA T (2 h) Feridex 11.2 Human NSC 4 × 105 (1 μL) Str 1 d 3.6 ± 2.1 2.3 ± 0.42
Daadi et al. [26]
(2009)
Rat
(Sprague-Dawley)
MCDA T (30 mi; 1 h) Feridex 11.2 Human ESC 5 × 104-106 (1 μL) Str 2 d 11.5 ± 7.2 32.4 ± 12.3
Lee et al. [19] (2009) Rat (Wistar) FOT2 N/A MPIO 11.2-27.9 Human MSC 2 × 104 IC 2 d N/A N/A
Resovist 2 × 106 V
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Table 1 Motor performance after therapy with stem cells labeled by iron oxide nanoparticles in experimental designs of stroke (Continued)
Walczak et al. [25]
(2008)
Rat (Wistar) MCDA T (2 h) Feridex 11.2 Rat
(bone marrow)
MSC 106 (2 μL) V 30
mi
N/A N/A
Kim et al. [24] (2008) Rat (Sprague-
Dawley)
MCDA T (2 h) Feridex 11.2 Human MSC 105 IC 7d N/A N/A
Guzman et al. [23]
(2008)
Rat (Sprague-
Dawley)
MCDA T (1 h) Feridex 11.2 Mice NSC 2 × 105 (2 μL) Str −7 d N/A N/A
Rice et al. [14] (2007) Mice (C57B/6) MCDA T (1 h) Feridex 11.2 Mice fMSC 5 × 102 IHp 1 d 3.7 ± 0.99 2.3 ± 0.48
5 × 103 Str
Jendelová et al. [18]
(2004)
Rat (Wistar) FOT2 N/A Endorem 11.2 Rat ESC 2 × 105 IC 7 d N/A N/A
MSC 2 × 106 V
Hoehn et al. [22]
(2002)
Rat (Wistar) MCDA T (1 h) Sinerem 20.0 N/A ESC 2 × 3 × 104 Str 14 d N/A N/A
CC
BMSC, bone marrow-derived mesenchymal stromal cell; CC, corpus callosum; d, day; ESC, embryonic stem cell; fMSC, fat mesenchymal stem cell; FOT1, photothrombosis model (rose Bengal 20 mg/kg, 20 minutes,
540 nm light); FOT2, photothrombosis model (rose Bengal 10 mg/kg, 10 minutes, light 327 to 650 nm; h, hour; IC, intracortical; ICAO, occlusion of the internal carotid artery; IHp, intrahippocampal; MCDA, occlusion of
the middle cerebral artery; mi, minute; MSC, mesenchymal stem cell; N/A, not identified; NSC, neural stem cell; OAF, femoral artery occlusion; P, permanent; PPA, ; rMAPC, rat multipotent adult progenitor cell; SPION,
Superparamagnetic iron oxide nanoparticles; MCDA, occlusion of the middle cerebral artery; OAF, femoral artery occlusion; ICAO, Occlusion of the internal carotid artery; FOT1, photothrombosis model (rose Bengal 20
mg/ kg, 20min, 540nm light); FOT2, photothrombosis model (rose Bengal 10 mg/ kg, 10min, light 327 - 650nm; T, temporary; P, Permanent; mi, minute; h, hour; N/A, not identified; MOCO7F, MPIO, NSC, neural stem
cell; BMSC, bone marrow-derived mesenchymal stroma cell; MSC, mesenchymal stem cells; rMAPC, rat multipotent adult progenitor cell; ESC, embrionary stem cell; Str, intrastriatum; V, endovascular; IC, intracortical;
CC, Corpus callosum; IHp, intrahippocampal; fMSC, fat mesenchymal stem cell; d, days.
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Figure 3 Functional outcome after stem cell therapy in stroke
model. Three-dimensional pie chart of stem cell distribution with behavior
score after rodent focal ischemia. ESC, embryonic stem cell; MSC,
mesenchymal stem cell; NSC, neural stem cell.
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concentrations ranged between 0 g/mL [13] and
2,800 g/mL [22] of Fe2+. In regard to deployment of the
SC/SPION procedure, the selected studies used cerebral
application in specific regions such as striatum [14,15,
17,20-23,26,27,29,31,33], hippocampus [14], and corpus
callosum [22] and in non-specific regions such as intra-
ventricular/cortical regions [11,12,16,18,19,24,28-30,34].
Some studies [13,16,19,25,32,34] conducted cerebral, in-
ternal carotid artery implementation in peripheral,
femoral artery, and vascular bed [13,18,25,34]. The aver-
age time between the ischemic event and therapy with
SC/SPION was roughly 3.43 days or 82 hours, but some
studies [13,34] underwent implantation immediately
after intracortical [34] or endovascular [13]. Another
study [22] performed the therapy 14 days after the is-
chemic event.Figure 4 Forest plot of behavior score of stem cell therapy at preclin
standardized mean difference; W, weight.The most significant functional recovery was 14 days
after implantation of SC/SPION described by Gutiérrez-
Fernández et al. [34]. Therapeutic efficacy was evaluated
during the experimental model (Figure 4) in only five
studies [13,26,27,29,34] that conducted behavioral testing
based on adaptations of scales of clinical neurology; other
studies have evaluated the efficiency of the model by the
analysis of MRI and also by histological analysis (Table 2).
No significant influence related to route of administration
on either structural or functional outcome was seen.
For the functional outcome, because the Cochran Q
test has a low power when the number of studies is
small, we consider the I2 statistic to evaluate the hetero-
geneity of studies. Considering the raw mean difference,
we obtained I2 = 19.6% (confidence interval (CI) = 0% to
83.3%, P = 0,2898), indicating that the studies were homo-
geneous. Therapy was considered effective, as the com-
bined average difference observed was −1.6255 (CI =
−1.8923 to −1.3588, Z statistic = −11.9446, P <0.0001).
However, because of experimental methodological differ-
ences, we also analyzed the standardized mean differences
considering the pooled standard deviation of two groups
(Figure 4). In this analysis, the heterogeneity between stud-
ies was evident: I2 = 69.1% (CI = 20.7% to 88%, P = 0.0115).
However, the conclusions had the same raw mean differ-
ence because the combined standardized mean difference
observed in fixed effect model was −1.9161 (CI = −2.2383
to −1.5939, Z statistic = −11.6564, P <0.0001). Despite the
high heterogeneity among studies on the effectiveness of
cell therapy in the cerebrovascular accident model, the
analysis indicated a significant neuroprotective effect.
All selected studies [11-34] evaluated the cell homing by
using MRI and histological analyses to validate anatomical
and functional improvement from results in image evalu-
ation (Table 2). Overall, selected studies regarding MRI
found SC/SPIONs homing to ischemic area in several time
points and routes. In MRI, the magnetic field ranged from
1.5 T [19,27,33] to 9.4 T [13,14,20,21,25]. The studies used
several protocols of sequence and weighted and thickness
images, and the most widely used was a T2-weighted three-
dimensional spin echo image of 1 mm.
To assess the extent of injury caused by the induced is-
chemic stroke, nine studies [11,16,17,19-21,27,30,34] wereical stroke. CI, confidence interval; SD, standard deviation; SMD,
Table 2 In vivo and Ex vivo image data
Reference Magnetic resonance image HistologicaI image
MF (T) Sequence Weighted images
(TR/TE;ms)
FOV; MT; ST Results Date (days) Assay Results Date (days)
Wen et al. [33] (2014) 1.5 FSE T2:2000/100 40; 256×256; 1mm H+ 7,14,21,28,35,42 PB; GFAP MAP2 H+ 42
FFE T2*:600/18.31
Shichinohe et al. [17] (2013) 7.0 Spin echo T2:2500/60 30×30; 512×512; 1mm H+ 2,8,14,28,49 HE; TB; GFAP NeuN H+ N/A
Tarulli et al. [32] (2013) 3.0 FSE T2:8/70 30×30; 512×512; 1mm H+ 7,14 PB H+ 15
Zhang et al. [16] (2013) 7.0 N/A N/A N/A; N/A; H+ 1,2,3,4,5,6,7 PB H+ N/A
Liu et al. [31] (2013) 3.0 GRE T2*:2560/6.0 6.0; N/A; 1.6 mm H+ 1, 7,21 PB; BrdU;SOX-2 H+ 7,21
Lu et al. [11] (2013) 3.0 T2WI T2*: 5000/60 200;320×320; 2mm H+ 1, 7,14, 21, 28 HE; PB H+ 28
DWI
Kamiya et al. [30] (2013) 7.0 3D GRE T2*: 100/10 50×50; 256×256; 5mm H+ 1h, 1, 3, 7 BB; PKH26 H+ 7
T2WI T2*: 2000/60 50×50; 256×128; 5mm LL
Riegler et al. [13] (2012) 9.4 3D GRE T2:6000/105 70×70; 512×512; 1mm H+ 24h PB H+ 21
T2*:6000/105
Detante et al. [29] (2012) 2.35 SE-DW DW:2000/80 N/A; 234×234; 1mm H+ 1, 15, 28 GFAP H+ 1, 15, 28
T2*:400/25 Tr+
Yang et al. [28] (2011) 3.0 MPGR T2*:596/16 292×290; 0.7mm H+ 1,15 GFAP;PB H+ N/A
Wang et al. [15] (2011) 3.0 N/A T2: 5840/104 45×45; 256×256; 1.5mm H+ 1, 3 GFAP;PB H+ 1, 7, 30
Tr+ Tr+
Gutiérrez-Fernandez et al. [34]
(2011)
7.0 RARE T2 N/A H+ 24h, 14 NeuN H+ N/A
LL GFAP LL
VEGF
Vandeputte et al. [21] (2010) 9.4 N/A T2: N/A N/A H+ 24H, 2-18 MAP2 H+ N/A
Tr+
Reddy et al. [12] (2010) Turbo Spin echo T2: 2128/80 230×230; 700×625, 1mm, H+ 4, 16 PB H+ 16
3.0 T2: 2548/80 80×80;94×94; 1.5mm Tr+
DW: 4763/50 80×80;94×94; 1.5mm
Crabbe et al. [20] (2010) 9.4 2D MSME T2: 6000/10; DW:
1500/27
4.0×4.0; 156×156; 0.8 mm H+ 12h, 10 MAP2 H+ N/A
N/A; N/A; 1mm Tr+
Song et al. [27] (2009) 3D spin echo T2: 3500/80 60×60; 256×160 2.0mm N/A N/A N/A N/A N/A
PB
1.5 T2:50/20 80× 80; 256×160; 2mm H+ −1, 1, 3, 7,14, 21,
28
NeuN H+ 1, 28
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Table 2 In vivo and Ex vivo image data (Continued)
GFAP Tr+
BrdU
Daadi et al. [26] (2009) 7.0 2D – spin echo T2: 4000/82,5 5cm; 256×256; 0.6 mm H+ 2, 7, 14, 28, 60 hNSC H+ 60
LL GFP LL
NeuN
Lee et al. [19] (2009) 1.5 Turbo spin echo T2: 2000/81 5cm; 512×512; 1.5mm H+ −1, 1, 5, 12 hVim H+ N/A
GRE T2*: 280/20 fMSC Tr+
Walczak et al. [25] (2008) 4.7 or
9.4
3D Spin echo T2: 1300/98 34×22×11; 128×64×3; 0.35mm H+ −1h, 2h-1 BrdU H+ N/A
GRE T2*: 300/5 10×16; 128×128 Tr+
Kim et al. [24] (2008) 4.7 3D Spin echo; T1; N/A 4×3 H+ 2, 7-70 hMSC H+ Cell in core of
lesion
RARE; Flash T2: 600/14 256×192; 1mm Tr+
T2*:758/30
Guzman et al. [23] (2008) 4.7 Spin echo T2:2500/45 40; 256×256; 1mm H+ −4, 3, 7,24 AP BrdU; GFAP;
βTubulin
H+ N/A
3D GRE T2*:600/5 Tr+
Rice et al. [14] (2007) 7.0 or
9.4
Spin-echo
multislice
T2: 1,0; N/A 3.5cm; 128×128; 1mm H+ 24h, 14 fMSC H+ N/A
GFP Tr+
Jendelove et al. [18] (2004) 4.7 Turbo spin echo T2:2000/42.5 3,5cm; 256×256; 0,5mm H+ 14-49 MSC* H+ N/A
ESC Tr+
GFP
Hoehn et al. [22] (2002) 7.0 2D Multislice T2: 200/20 20×12×10 256×256×128; 0.5-
0.7mm
H+ 6, 8, 11, 16 ESC H+ N/A
3D Flash GFP Tr+
2D, two-dimensional; 3D, three-dimensional; AP, acidic protein; BrdU, bromodeoxyuridine; DWI, diffusion weighted imaging; ESC, (mouse) embryonic stem cell; FFE, fast field echo; fMSC, fetal mesenchymal stem cell;
FOV, field of vision; FSE, fast spin echo; GE, gradient echo ; GFAP, glial fibrillary acidic protein; GFP, green fluorescence protein; GRE, gradient echo; h, hour; HE, hematoxylin and eosin; hMSC, human mesenchymal
stem cell; hNSC,human embryonic stem cell-derived human neural stem cell; H+, homing (migration to target site); hVim, human vimentin antibody; LL, loss lesion; MAP2, microtubule-associated with protein 2; MF,
magnetic field; MPGR, multiplanar gradient recalled acquisition in the steady state; MSC, rat bone marrow stromal cell; MSME, 2D-Multislice-multiecho ; MT, matrix; N/A, not identified; NeuN, neuronal nuclei; PB,
Prussian blue; SE, diffusion-weighted; ST, thickness; RARE, rapid acquisition with relaxation enhancement; T, Tesla; T2WI, -weighted magnetic resonance imaging; T2*, star weighted imaging; TB, Trypan blue; TE, echo
time; TR, repetition time; Tr+, tracking (possibility of cellular trace).
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Results of microscopic analysis of the lesion extent were
consistent with findings obtained in the analysis by MRI.
Location and extent of injury did not differ considering
the experimental model. However, the evaluation of agree-
ment between histology and imaging examination indicated
that only three studies [26,30,34] found a decrease in lesion
area treated with stem cells. Kamiya et al. [30] and Gutiér-
rez-Fernández et al. [34] agreed in the short interval be-
tween the induction of ischemic stroke and transplantation;
that is, they performed the transplantation 90 minutes after
induced ischemic stroke; however, Daadi et al. [26] carried
out the transplantation 2 days after induced ischemic stroke.
In the study by Gutiérrez-Fernández et al. [34], lesion area
reduction was independent of the route of administration
observed, as Daadi et al. [26] and Kamiya et al. [30] admin-
istrated stem cells only in the lesion area.
The homing process of cells used as a therapy was mea-
sured in 13 studies [11,12,14,16,18,19,21,24-27,32,33] by
Prussian blue staining. Correlation analysis between the lo-
cation of labeled cells on MRI and location shown on histo-
logical analysis indicated agreement between the analyses as
well as the homing of positive cells to the area of interest.
In addition the positive cells homing reached the
injured organ viability by Prussian blue staining, three
studies [14,18,26] assessed expressions by using the
green fluorescent protein (GFP) and in all cases the sites
indicated by MRI were in agreement. These results con-
firmed the location of cells and the maintenance of cell
viability. Changes in the microenvironment of the lesion
reported by four authors [25,27,31,34] that observed in-
crease labeled for bromodeoxyuridine (BrdU) and cell
proliferation process. The study by Walczak et al. [25]
reported an increase that was positive for BrdU in the
perivascular region at the first day after transplantation,
and for 10 days after transplantation, positivity was
maintained, including more distant regions of the vascu-
lar bed. However, despite remaining positive for BrdU,
the signal intensity of labeled cells was not maintained
in resonance examination. Besides the BrdU labeling,
two authors [27,34] conducted labeled for the expression
of glial fibrillary acidic protein (GFAP), which is a
marker of increased activity of glial cells, especially as-
trocytes and neuronal nuclei marker (NeuN). In
addition, these two studies [27,34] reported increased
expression of markers used after transplantation of
MSCs, thus indicating increased cell proliferation, glial
activity, and preservation of the injured area. In the
study by Gutiérrez-Fernández et al. [34], animals treated
with MSC markers regardless of the route of administra-
tion of labeled cells expressed an increase in addition to
BrdU compared with control groups (137 ± 9.9 versus
51 ± 9.2; P <0.05). There was also an expression of in-
crease in NeuN, GFAP, and vascular endothelial growthfactor (VEGF) after 14 days of transplantation in the
penumbra area that contributed toward reducing the in-
jured area and inflammatory markers such as tumor ne-
crosis factor-alpha (TNF-α) and interleukin-6 (IL-6).
These results appear to correlate with an improvement in
neurological scores observed in transplanted animals (3.4 ±
0.89 versus 1.7 ± 0.53; P <0.05). The correlation between in-
creased tissue protective factors in transplanted animals
and improved neurological scores was also found in the
study by Detante et al. [29] that reported an increase of
GFAP in animals that received MSCs and also an im-
provement in neurological scores in comparison with the
control group (3.3 ± 1.5 versus 1.4 ± 0.8; P <0.05), thus
confirming the results of Gutiérrez-Fernández et al. [34].
Although some studies [15,17,33] did not conduct behav-
ioral assessment, others found an increase in the expres-
sion of GFAP and increased microtubule-associated with
protein 2 (MAP2), which indicate an improvement in pen-
umbra area.
Discussion
All selected studies with behavioral tests reported func-
tional improvement associated with the presence of the
MS/SPION complex in ischemic area and neurorepair
histological changes. The meta-analysis of these studies
showed that MS/SPIONs were efficient for treatments,
although few studies applied neurological score or be-
havior tests. Recent reviews [35-37] also observed thera-
peutic efficacy of stem cells in several preclinical models
of stroke but recognized that many fundamental ques-
tions related to cell characterization, cell dosage, cell
fate, biodistribution, safety indices, outcome measures,
and so on are critical for the successful development of
a cell product. The labeling process of stem cells with
iron oxide could increase cytotoxicity, but improvement
of in vivo homing and tracking image techniques of cells.
Could stem cells influence neurorepair after stroke?
Stem cells come from various sources, and although they
share some common properties, they also differ in many re-
spects and behave differently in terms of their rate of differ-
entiation, trophic factor secretion, and their stimulation of
endogenous processes when in a pathologic environment
[38]. The key source and type of stem cells of the selected
studies were human (bone marrow) and mesenchymal. Al-
though the study by Daadi et al. [26] had a better behavior
status, using neural embryonic stem cells, the majority of
studies used MSCs (60%), some studies used neural stem
cells (20%) or embryonic stem cells (20%), and no studies
compared the different cell types in the same experiment
(Figure 3).
The dose or concentration, route, and fate cells of samples
of ranged from 5 × 102 (Rice et al. [14] 2007) to 107 (Kamiya
et al. [30] 2013), and intrastriatal was the main route used.
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chymal stromal cells for ischemic stroke observed that the
range of MSCs was from 3.5 × 104 to 4.3 × 107, and intra-
venous was the main route reported in studies. Yavagal et al.
[39] evaluated the dose and route of MSCs after 1 hour or
24 hours of ischemic injury per 1 hour of occlusion of the
middle cerebral artery, and observed that intra-arterial ad-
ministration of 1 × 105 MSCs after 24 hours of stroke was
more efficient in ameliorating neurological deficits in rodent
cerebral ischemia, narrowing change of blood flow, reducing
infarct volume, and improving functional status. All selected
studies found positive cell tracking of SC/SPIONs by mag-
netic resonance and histological methods for penumbra area
after several routes and times of grafting. Other studies
[40,41] and systematic reviews [35,37] also observed several
studies with positive stem cell homing to penumbra area
after 7 days of stroke. The grafting route can influence the
time point and the biodistribution of stem cells and further
the aggregation process [37] as previously discussed.
Stem cell biology of repair in preclinical ischemia model
Among all the lines of stem cells used therapeutically,
MSCs can express neuronal markers in vivo as well as
trophic factors such as brain-derived neurotrophic factor
(BDNF), glial-derived neurotrophic factor (GDNF), VEGF,
neurotrophin-3 (NT3), and fibroblast growth factor (FGF),
and thrombospondins are secreted by MSCs in response to
the local microenvironment. These factors, along with
their stimulation of neurogenesis and angiogenesis immu-
nomodulation, promote functional recovery [42]. In this
sense, these stem cells also stimulate astrocytes, that this
past years has been used as a therapeutic target, because its
role in maintaining neuronal function and effective
endogenous repair [43]. Most of the selected studies
[11,18,19,21,24-27,32-34] observed an increase of trophic
factors, reduction of the area of injury, inflammatory
markers such as TNF-α and IL-6, increase in protein ex-
pression, proliferative activity, and increased activity of glial
cells.
Iron toxicity in stem cells
Although reports evaluated the adoption of methods to
assess the ability for differentiation and presence of cyto-
toxicity, the description of these methods and their re-
sults are brief and sometimes treated as irrelevant. This
agrees with an understanding that such assessments are
not the central idea of the study, because this is a strat-
egy to validate the quality of the cells after labeling with
SPIONs, which validate the use for the evaluation of
in vivo cell tracking and homing.
The absence of reported cytotoxicity may result from
the adoption of methods already established for cultiva-
tion and labeling of the cells. A review by Arora et al. [44]
reported a study that aimed at standardizing cell labelingwith SPIONs, and indicated a low incidence of labeled
cells in cytotoxicity because of the concentration of
SPIONs, number of cells to be standardized, SPION rela-
tionship/cell type, method of internalization, and marking
time. This confirms the findings observed in the selected
articles. The low incidence of cell death in in vitro cellular
genotoxicity and lack of changes in differentiation ability,
when contemplating the need for biocompatibility of
nanomaterials, contribute to their promising applicability
as a contrast agent in stem cell studies [45]. As the se-
lected studies focused on assessing the ability of mapping
in vivo homing, cell tracking, and therapeutic potential,
the approach of inducing toxicity remained in the back-
ground, and was guided by methodological descriptions,
which do not allow full clarification of the interaction effects
of SPIONs with cellular structures, until the standardization
and safety described are achieved. Therefore, because of
the brief description of investigation of the cytotoxic effects
on marking with SPIONs found in selected studies, our
commitment was to further discuss this subject.
Our study has limitations as the internal validity of
choice in select only data published in three major data-
base and Cochrane library. In addition, we used an obser-
vational approach rather than an experimental one, which
enables one to report only associations rather than caus-
ation. Although our search strategy was designed to be ex-
haustive, it is possible that some published studies were
missed; nonetheless, our study is likely to have captured
the majority of reports in this field and represents the
most complete review to date of the use of SC/SPIONs in
experimental stroke.
Safety represents a critical concern before stem cells are
allowed to be extensively used in clinical settings. Re-
cently, a meta-analysis [38] of clinical trials searched in
MEDLINE and EMBASE and by the Cochrane Central
Register of Controlled Trials (June 2014) did not detect
associations between MSC treatment and development of
acute infusional toxicity, organ system complications, in-
fection, death, or malignancy. Notwithstanding these im-
portant caveats, our analyses provide a support for some
hypotheses regarding the biology of stem cell-based ther-
apies. There is paucity evidence of use of coils with SPION
to cell tracking, but this evidence show up the best ‘future’
outlook in neurological clinical stem cell therapy, because
it reduces iron concentration and assists the cell tracking
to the brain damage area, and modulates electrophysi-
ology of this area to repair. This review did not identify
the use of coils in the selected articles, but explores the
evidence regarding the therapeutic use of SPION in pre-
clinical models of stroke.
Conclusions
Selected studies show great promise for cell transplantation
as a new therapeutic modality for stroke. Beneficial effects of
Nucci et al. Stem Cell Research & Therapy  (2015) 6:27 Page 12 of 13stem cells might include neuroprotection, angiogenesis, in-
flammatory, and immune responses. Although animal stud-
ies and reviews demonstrated that impaired neural function
has been significantly improved after administration of vari-
ous stem cells, few clinical trials have found similar benefits.
A better understanding of the mechanisms of stem cells for
treatment of stroke will help resolve the heterogeneity of re-
sults. In the future, stem cells combined with gene therapy
or rt-PA will play an important role in experimental and
clinical settings.
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